

PRESS RELEASE



FOR IMMEDIATE RELEASE:

October 2, 2018

CONTACT:

Mary Ellen Grant

(916) 396-2221

mgrant@calhealthplans.org

CAHP Statement: Renewed SB 17 Lawsuit Signals PhRMA's Continued Unwillingness to Acknowledge Their Outsized Role in the High-Priced Drug Crisis

Sacramento, CA – The Pharmaceutical Research and Manufacturers of America (PhRMA) has re-filed its lawsuit against SB 17, California's drug price transparency legislation. PhRMA's action comes just one month after a federal judge dismissed the organization's previous lawsuit and offers a clear sign that the group intends to continue its efforts to keep patients in the dark about prescription drug pricing.

CAHP CEO and President Charles Bacchi offered the following statement in response to the announcement:

“High-priced prescription drugs continue to be one of the leading factors driving up health care costs for Californians. With the passage of SB 17, the State Legislature joined the broad and bipartisan coalition of leaders working to address this high-priced drug crisis - unfortunately, Pharma's decision to re-file its already dismissed lawsuit against the landmark legislation proves that they remain unwilling to be a part of the solution.

“CAHP has stood strongly behind SB 17 from the start and we will continue to do so throughout this new litigation. SB 17 shines a light on pricing tactics that have long lived in the dark and we will continue fighting to keep that light on.”

###

CAHP is a statewide association representing 48 full-service health plans. Through legislative advocacy, education and collaboration with other member organizations, CAHP works to sustain a strong environment in which our member plans can provide access to products that offer choice and flexibility to the more than 25 million members they serve. For more information, please visit <http://www.calhealthplans.org/> or call (916) 552-2910.